A retrospective study evaluating the efficacy and safety of anlotinib monotherapy or anlotinib combined chemotherapy in cervical cancer patients who have disease progressed or metastasis after chemoradiotherapy
Latest Information Update: 27 Jul 2021
At a glance
- Drugs Catequentinib (Primary) ; Antineoplastics
- Indications Cervical cancer
- Focus Therapeutic Use
- 27 Jul 2021 New trial record
- 08 Jun 2021 Results (n=28; data cut off date: Dec 31 2020), presented at the 57th Annual Meeting of the American Society of Clinical Oncology.